Bicalutamide and third-generation aromatase inhibitors in testotoxicosis

Anne M. Lenz, Dorothy Shulman, Erica Eugster, Samar Rahhal, John Fuqua, Ora H. Pescovitz, Katherine A. Lewis

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Testotoxicosis, a form of gonadotropin-independent precocious puberty, results from an activating mutation of the luteinizing hormone receptor expressed in testicular Leydig cells. Affected males experience early testosterone secretion, virilization, advancing bone age, and resultant short stature. Recently, the use of combination therapy with a potent antiandrogen agent (bicalutamide) and a third-generation aromatase inhibitor (anastrozole or letrozole) was reported to yield encouraging short-term results. We present here the results of longer-term treatment (4.5 and 5 years) with this combination therapy in 2 boys who demonstrated that it is well tolerated, slows bone-age advancement in the face of continued linear growth, and prevents progression of virilization.

Original languageEnglish
JournalPediatrics
Volume126
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Aromatase Inhibitors
Virilism
letrozole
LH Receptors
Bone and Bones
Androgen Antagonists
Leydig Cells
Testosterone
Therapeutics
Mutation
Growth
Sexual precocity
bicalutamide

Keywords

  • Age determination by skeleton
  • Aromatase inhibitors
  • Bicalutamide
  • Gonadal disorders
  • Precocious puberty

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. / Lenz, Anne M.; Shulman, Dorothy; Eugster, Erica; Rahhal, Samar; Fuqua, John; Pescovitz, Ora H.; Lewis, Katherine A.

In: Pediatrics, Vol. 126, No. 3, 09.2010.

Research output: Contribution to journalArticle

Lenz, Anne M. ; Shulman, Dorothy ; Eugster, Erica ; Rahhal, Samar ; Fuqua, John ; Pescovitz, Ora H. ; Lewis, Katherine A. / Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. In: Pediatrics. 2010 ; Vol. 126, No. 3.
@article{d294addc886640e890b5345b95ba6ca0,
title = "Bicalutamide and third-generation aromatase inhibitors in testotoxicosis",
abstract = "Testotoxicosis, a form of gonadotropin-independent precocious puberty, results from an activating mutation of the luteinizing hormone receptor expressed in testicular Leydig cells. Affected males experience early testosterone secretion, virilization, advancing bone age, and resultant short stature. Recently, the use of combination therapy with a potent antiandrogen agent (bicalutamide) and a third-generation aromatase inhibitor (anastrozole or letrozole) was reported to yield encouraging short-term results. We present here the results of longer-term treatment (4.5 and 5 years) with this combination therapy in 2 boys who demonstrated that it is well tolerated, slows bone-age advancement in the face of continued linear growth, and prevents progression of virilization.",
keywords = "Age determination by skeleton, Aromatase inhibitors, Bicalutamide, Gonadal disorders, Precocious puberty",
author = "Lenz, {Anne M.} and Dorothy Shulman and Erica Eugster and Samar Rahhal and John Fuqua and Pescovitz, {Ora H.} and Lewis, {Katherine A.}",
year = "2010",
month = "9",
doi = "10.1542/peds.2010-0596",
language = "English",
volume = "126",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "3",

}

TY - JOUR

T1 - Bicalutamide and third-generation aromatase inhibitors in testotoxicosis

AU - Lenz, Anne M.

AU - Shulman, Dorothy

AU - Eugster, Erica

AU - Rahhal, Samar

AU - Fuqua, John

AU - Pescovitz, Ora H.

AU - Lewis, Katherine A.

PY - 2010/9

Y1 - 2010/9

N2 - Testotoxicosis, a form of gonadotropin-independent precocious puberty, results from an activating mutation of the luteinizing hormone receptor expressed in testicular Leydig cells. Affected males experience early testosterone secretion, virilization, advancing bone age, and resultant short stature. Recently, the use of combination therapy with a potent antiandrogen agent (bicalutamide) and a third-generation aromatase inhibitor (anastrozole or letrozole) was reported to yield encouraging short-term results. We present here the results of longer-term treatment (4.5 and 5 years) with this combination therapy in 2 boys who demonstrated that it is well tolerated, slows bone-age advancement in the face of continued linear growth, and prevents progression of virilization.

AB - Testotoxicosis, a form of gonadotropin-independent precocious puberty, results from an activating mutation of the luteinizing hormone receptor expressed in testicular Leydig cells. Affected males experience early testosterone secretion, virilization, advancing bone age, and resultant short stature. Recently, the use of combination therapy with a potent antiandrogen agent (bicalutamide) and a third-generation aromatase inhibitor (anastrozole or letrozole) was reported to yield encouraging short-term results. We present here the results of longer-term treatment (4.5 and 5 years) with this combination therapy in 2 boys who demonstrated that it is well tolerated, slows bone-age advancement in the face of continued linear growth, and prevents progression of virilization.

KW - Age determination by skeleton

KW - Aromatase inhibitors

KW - Bicalutamide

KW - Gonadal disorders

KW - Precocious puberty

UR - http://www.scopus.com/inward/record.url?scp=77956279347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956279347&partnerID=8YFLogxK

U2 - 10.1542/peds.2010-0596

DO - 10.1542/peds.2010-0596

M3 - Article

C2 - 20713483

AN - SCOPUS:77956279347

VL - 126

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 3

ER -